Zacks Investment Research downgraded shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research report released on Saturday morning.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

PRQR has been the topic of a number of other reports. HC Wainwright restated a buy rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. ValuEngine upgraded ProQR Therapeutics N.V. from a strong sell rating to a sell rating in a research report on Friday, September 1st. Chardan Capital reiterated a neutral rating on shares of ProQR Therapeutics N.V. in a research report on Sunday, September 17th. JMP Securities raised their target price on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an outperform rating in a report on Tuesday, September 26th. Finally, Leerink Swann reissued an outperform rating and issued a $12.00 target price (up previously from $10.00) on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $16.50.

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) opened at 4.80 on Friday. The firm’s market cap is $115.70 million. The stock has a 50 day moving average of $5.20 and a 200 day moving average of $5.05. ProQR Therapeutics N.V. has a 12 month low of $3.65 and a 12 month high of $8.70.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers ProQR Therapeutics N.V. (PRQR) to Hold” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/zacks-investment-research-lowers-proqr-therapeutics-n-v-prqr-to-hold/1604298.html.

Large investors have recently made changes to their positions in the company. Redmile Group LLC grew its holdings in shares of ProQR Therapeutics N.V. by 2.8% in the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after acquiring an additional 43,050 shares during the period. Janus Henderson Group PLC purchased a new position in ProQR Therapeutics N.V. in the 2nd quarter valued at approximately $2,028,000. Finally, Artal Group S.A. increased its stake in ProQR Therapeutics N.V. by 25.0% in the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after purchasing an additional 100,000 shares in the last quarter. 35.93% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get a free copy of the Zacks research report on ProQR Therapeutics N.V. (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.